Related Experiment Videos
Melphalan, vincristine, and 5-FU in advanced colonic carcinoma: results of a pilot study
Abstract:
The results of treatment with melphalan, vincristine, and 5-FU (MVF) in 32 patients with advanced colonic carcinoma are reported. The objective response rate among 31 patients with measurable disease was 16% (five patients responded). The projected survival for all 32 patients was 277 days. Patients with objective response to MVF had a projected survival of 314 days, significantly longer than the survival of patients with no response to therapy, 84 days (P = 0.01). While toxic effects were mild with MVF, this regimen appears to have greater activity in advanced colonic carcinoma than therapy with 5-FU alone or in combination with nitrosoureas.
Insights
The melphalan, vincristine, and 5-FU (MVF) regimen showed a 16% objective response rate in advanced colonic carcinoma. Responding patients experienced significantly longer survival, indicating MVF
Area of Science:
- Oncology
- Gastrointestinal Oncology
- Clinical Pharmacology
Background:
- Advanced colonic carcinoma presents significant treatment challenges.
- Evaluating novel combination chemotherapy regimens is crucial for improving patient outcomes.
Purpose of the Study:
- To assess the efficacy and safety of melphalan, vincristine, and 5-fluorouracil (MVF) in patients with advanced colonic carcinoma.
- To compare the survival outcomes of patients who responded to MVF therapy versus those who did not.
Main Methods:
- A cohort of 32 patients with advanced colonic carcinoma received the MVF regimen.
- Objective response rate was assessed in 31 patients with measurable disease.
- Projected survival was calculated for all patients and stratified by response status.
Main Results:
- The objective response rate to MVF was 16% (5 out of 31 evaluable patients).
- Patients achieving an objective response had a significantly longer projected survival (314 days) compared to non-responders (84 days, P = 0.01).
- The MVF regimen was associated with mild toxic effects.
Conclusions:
- The MVF regimen demonstrates activity in advanced colonic carcinoma.
- Objective response to MVF is associated with a substantial improvement in projected survival.
- MVF may offer greater efficacy compared to 5-FU monotherapy or 5-FU combined with nitrosoureas in this patient population.